Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis

David M. Routman, Bhishamjit S. Chera, Gaorav P. Gupta

Research output: Contribution to journalReview articlepeer-review


Oligometastasis represents an intermediate disease stage between localized and widely metastatic cancer. Efficient identification of patients with oligometastasis remains a barrier for accrual on clinical trials of oligometastasis-directed therapy. Here we review the prospect of circulating tumor DNA-based monitoring to promote sensitive, specific, and cost-efficient detection of cancer recurrence during posttreatment surveillance. Thus, an impetus for the development and implementation of clinical-grade circulating tumor DNA assays should be for the positive impact they will have on clinical investigations of oligometastasis-directed therapy.

Original languageEnglish (US)
Pages (from-to)116-123
Number of pages8
JournalCancer Journal (United States)
Issue number2
StatePublished - Mar 1 2020


  • Biomarkers
  • circulating tumor DNA
  • oligometastasis
  • radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis'. Together they form a unique fingerprint.

Cite this